Medpace’s Post

The types of assessments used as primary, and key secondary, endpoints in Alzheimer's trials are complex and therefore subject to error in administration. Improving signal-to-noise ratio is critical. It is common to see error in administration from physicians with less trial experience as well as variation in administration from country to country. The continuous, in-trial, monitoring of assessments to look for error is a critical part of improving the signal-to-noise ratio in complex global trials.

Major trials have demonstrated that lecanemab, a drug developed by Eisai, can delay the progression of early-stage Alzheimer's disease. However, its effectiveness relies on early detection, which often requires specialised scans and medical examinations. Learn more: https://bit.ly/47dpzVA #HarleyStHearing #AlzheimersDisease #Lecanemab #EarlyDiagnosis #Eisai #BrainHealth

This is a very INTERESTING DISCUSSION! "Should Alzheimer’s be diagnosed without symptoms? Proposal to rely on blood tests roils scientists as some researchers seek to establish a single abnormal result on a set of biomarker-based tests as sufficient to diagnose the disease." Learn More in Nature | Nature Portfolio 👉 https://lnkd.in/eep27fVd "Controversy has erupted among researchers over an effort to adopt blood tests and brain scans for diagnosing #AlzheimersDisease, rather than the cognitive screening that has been used for decades." "Proponents of the change say that new biomarker tests can detect #Alzheimers at a very early stage — the best time to apply any treatments that are developed to reverse the disease. But critics say that, although the effort is well-intentioned, it means that people can be diagnosed with a single test, even if they have no symptoms of cognitive decline — and might never develop them." Weighing In: Nicolas Villain, Sorbonne University Clifford Jack, Mayo Clinic Andrea Bozoki, University of North Carolina at Chapel Hill School of Medicine Winston Chiong, University of California, San Francisco

In our newest #BlogPost, CEO & Founder Stella Sarraf, PhD, reflects on her recent conversation with Dan Doctoroff about the important role #synapses play in neurodegenerative diseases and their shared mission to offer hope to those affected. We are excited about our ongoing trials with #SPG302 in #ALS, and our plans to expand into #AlzheimersDisease and #schizophrenia, where synaptic dysfunction plays a significant role! Read here: https://lnkd.in/erA97avD #ALSawareness #SynapticFunction #PatientsFirst

In this randomized clinical trial, iron chelation with deferiprone accelerated Alzheimer disease progression. https://ja.ma/48CA0m7

Early Detection in Alzheimer’s Disease: Why It Matters Did you know that changes in the brain can begin years before memory symptoms appear? This is called the preclinical phase of Alzheimer’s disease, where amyloid—a protein linked to Alzheimer’s disease—accumulates silently. At Toronto Memory Program, we offer blood tests as part of clinical trials for asymptomatic individuals, those with mild symptoms, and those who have progressed beyond that. These tests help determine if amyloid is present and open the door to research opportunities focused on trying to prevent or slow Alzheimer’s disease. 🎥 Watch this video to learn more about the importance of early detection and how research is paving the way for a healthier future.

Application of Generative-AI in Retinal Disease Diagnosis: Generative-AI has evolved and transforming in many real-world applications such as medical imaging with good performance. Labeled images are costly to acquire in terms of time, labor and human expertise in real scenarios. I am extremely pleased to present today at Institute of Child Heath -Great Ormond St. Hospital for Children, London, UK - Uncertainty-aware Generative-AI (Vision model) strategies combined with the Monte Carlo Dropweights approach in vessel segmentation for diagnosing Retinopathy of Prematurity (ROP) - leading cause of childhood blindness.

The recent approval of new drug therapies not only signals a new era in treatment of Alzheimer’s Disease but also underscores the urgent need for innovations that will enable early screening for Mild Cognitive Impairment and accurate detection of all forms of dementia, including complex manifestations of Alzheimer’s Disease. Join David Bates, CEO of Linus Health, Joel Braunstein, MD, CEO of C2N Diagnostics, and Ian Kremer, Executive Director of LEAD Coalition this Thursday for an upcoming NEHI (Network for Excellence in Health Innovation) webinar as they delve into the groundbreaking advancements reshaping the landscape of diagnostics of Alzheimer’s and related dementias. Register now to gain invaluable insights into the future of Alzheimer’s care. I #AlzheimersDisease #AlzheimersAwareness #BrainHealth #Dementia #AlzheimersPrevention #AlzheimersInnovation

In this randomized clinical trial, iron chelation with deferiprone accelerated Alzheimer disease progression. https://ja.ma/40aA2y1

Check out this journal club video module discussing Resmetirom in the treatment of #NASH with Liver Fibrosis!